nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLC22A8—Mercaptopurine—Crohn's disease	0.196	0.344	CbGbCtD
Dabrafenib—SLCO1B1—Sulfasalazine—Crohn's disease	0.173	0.304	CbGbCtD
Dabrafenib—ABCG2—Sulfasalazine—Crohn's disease	0.137	0.241	CbGbCtD
Dabrafenib—ABCB1—Prednisone—Crohn's disease	0.0396	0.0695	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—Crohn's disease	0.0237	0.0417	CbGbCtD
Dabrafenib—Malignant melanoma—Azathioprine—Crohn's disease	0.00677	0.0352	CcSEcCtD
Dabrafenib—Abdominal pain lower—Mesalazine—Crohn's disease	0.00506	0.0264	CcSEcCtD
Dabrafenib—Uveitis—Azathioprine—Crohn's disease	0.00505	0.0263	CcSEcCtD
Dabrafenib—Polyp—Mercaptopurine—Crohn's disease	0.00487	0.0254	CcSEcCtD
Dabrafenib—Nephritis—Mesalazine—Crohn's disease	0.00471	0.0245	CcSEcCtD
Dabrafenib—SIK1—mouth—Crohn's disease	0.00448	0.127	CbGeAlD
Dabrafenib—Cyst—Mercaptopurine—Crohn's disease	0.00443	0.0231	CcSEcCtD
Dabrafenib—Rash generalised—Mesalazine—Crohn's disease	0.00378	0.0197	CcSEcCtD
Dabrafenib—Prurigo—Mesalazine—Crohn's disease	0.00348	0.0181	CcSEcCtD
Dabrafenib—Nephropathy—Mesalazine—Crohn's disease	0.00338	0.0176	CcSEcCtD
Dabrafenib—NEK11—lymph node—Crohn's disease	0.00306	0.0868	CbGeAlD
Dabrafenib—Polyp—Azathioprine—Crohn's disease	0.0029	0.0151	CcSEcCtD
Dabrafenib—Neoplasm—Mercaptopurine—Crohn's disease	0.00268	0.014	CcSEcCtD
Dabrafenib—Cyst—Azathioprine—Crohn's disease	0.00264	0.0138	CcSEcCtD
Dabrafenib—Hypomagnesaemia—Mesalazine—Crohn's disease	0.00253	0.0132	CcSEcCtD
Dabrafenib—Dermatitis acneiform—Prednisone—Crohn's disease	0.00249	0.013	CcSEcCtD
Dabrafenib—SIK1—skin of body—Crohn's disease	0.00248	0.0703	CbGeAlD
Dabrafenib—Nephritis interstitial—Mesalazine—Crohn's disease	0.00238	0.0124	CcSEcCtD
Dabrafenib—SIK1—mammalian vulva—Crohn's disease	0.00226	0.0641	CbGeAlD
Dabrafenib—LIMK1—lymph node—Crohn's disease	0.00219	0.0621	CbGeAlD
Dabrafenib—Rigors—Azathioprine—Crohn's disease	0.00216	0.0113	CcSEcCtD
Dabrafenib—Tubulointerstitial nephritis—Mesalazine—Crohn's disease	0.0021	0.0109	CcSEcCtD
Dabrafenib—Rash erythematous—Mesalazine—Crohn's disease	0.0021	0.0109	CcSEcCtD
Dabrafenib—RAF1—epithelium—Crohn's disease	0.00207	0.0588	CbGeAlD
Dabrafenib—Neoplasm malignant—Azathioprine—Crohn's disease	0.00207	0.0108	CcSEcCtD
Dabrafenib—Rash pustular—Mesalazine—Crohn's disease	0.00202	0.0105	CcSEcCtD
Dabrafenib—SIK1—lymphoid tissue—Crohn's disease	0.00201	0.0569	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—Crohn's disease	0.002	0.0567	CbGeAlD
Dabrafenib—RAF1—skin of body—Crohn's disease	0.00197	0.056	CbGeAlD
Dabrafenib—Gamma-glutamyltransferase increased—Mesalazine—Crohn's disease	0.00196	0.0102	CcSEcCtD
Dabrafenib—Pancreatitis—Mercaptopurine—Crohn's disease	0.00182	0.0095	CcSEcCtD
Dabrafenib—RAF1—mammalian vulva—Crohn's disease	0.0018	0.051	CbGeAlD
Dabrafenib—Bone disorder—Mesalazine—Crohn's disease	0.00178	0.00928	CcSEcCtD
Dabrafenib—Oropharyngeal pain—Mesalazine—Crohn's disease	0.00177	0.00921	CcSEcCtD
Dabrafenib—Hypocalcaemia—Mesalazine—Crohn's disease	0.00176	0.00915	CcSEcCtD
Dabrafenib—Embolism venous—Prednisone—Crohn's disease	0.00169	0.00879	CcSEcCtD
Dabrafenib—Lymphopenia—Prednisone—Crohn's disease	0.00166	0.00866	CcSEcCtD
Dabrafenib—Stomatitis—Mercaptopurine—Crohn's disease	0.00162	0.00842	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Mesalazine—Crohn's disease	0.00161	0.00838	CcSEcCtD
Dabrafenib—Neoplasm—Azathioprine—Crohn's disease	0.0016	0.00832	CcSEcCtD
Dabrafenib—RAF1—lymphoid tissue—Crohn's disease	0.0016	0.0453	CbGeAlD
Dabrafenib—RAF1—digestive system—Crohn's disease	0.00158	0.0448	CbGeAlD
Dabrafenib—Influenza like illness—Mesalazine—Crohn's disease	0.00156	0.00814	CcSEcCtD
Dabrafenib—BRAF—lymph node—Crohn's disease	0.00135	0.0384	CbGeAlD
Dabrafenib—Immune system disorder—Mercaptopurine—Crohn's disease	0.00134	0.007	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Mesalazine—Crohn's disease	0.00134	0.00699	CcSEcCtD
Dabrafenib—Alopecia—Mercaptopurine—Crohn's disease	0.00132	0.00685	CcSEcCtD
Dabrafenib—Malnutrition—Mercaptopurine—Crohn's disease	0.0013	0.00675	CcSEcCtD
Dabrafenib—Renal failure acute—Mesalazine—Crohn's disease	0.00126	0.00659	CcSEcCtD
Dabrafenib—Dermatitis bullous—Mesalazine—Crohn's disease	0.00122	0.00636	CcSEcCtD
Dabrafenib—Anaemia—Mercaptopurine—Crohn's disease	0.0012	0.00624	CcSEcCtD
Dabrafenib—SLCO1B1—digestive system—Crohn's disease	0.00118	0.0335	CbGeAlD
Dabrafenib—Leukopenia—Mercaptopurine—Crohn's disease	0.00116	0.00604	CcSEcCtD
Dabrafenib—SIK1—lymph node—Crohn's disease	0.00113	0.0321	CbGeAlD
Dabrafenib—Arthralgia—Mercaptopurine—Crohn's disease	0.0011	0.00575	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.0011	0.00571	CcSEcCtD
Dabrafenib—Blood creatinine increased—Mesalazine—Crohn's disease	0.00109	0.0057	CcSEcCtD
Dabrafenib—Pancreatitis—Azathioprine—Crohn's disease	0.00109	0.00566	CcSEcCtD
Dabrafenib—Dry skin—Mesalazine—Crohn's disease	0.00107	0.00558	CcSEcCtD
Dabrafenib—Abdominal pain upper—Mesalazine—Crohn's disease	0.00107	0.00556	CcSEcCtD
Dabrafenib—Abdominal discomfort—Azathioprine—Crohn's disease	0.00106	0.00553	CcSEcCtD
Dabrafenib—Oedema—Mercaptopurine—Crohn's disease	0.00106	0.00551	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00105	0.00548	CcSEcCtD
Dabrafenib—Nasopharyngitis—Mesalazine—Crohn's disease	0.00104	0.00544	CcSEcCtD
Dabrafenib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00104	0.00539	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00103	0.00536	CcSEcCtD
Dabrafenib—Skin disorder—Mercaptopurine—Crohn's disease	0.00103	0.00535	CcSEcCtD
Dabrafenib—Pancreatitis—Mesalazine—Crohn's disease	0.000989	0.00515	CcSEcCtD
Dabrafenib—Infestation—Azathioprine—Crohn's disease	0.000988	0.00515	CcSEcCtD
Dabrafenib—Infestation NOS—Azathioprine—Crohn's disease	0.000988	0.00515	CcSEcCtD
Dabrafenib—Abdominal discomfort—Mesalazine—Crohn's disease	0.000967	0.00504	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000963	0.00502	CcSEcCtD
Dabrafenib—Neutropenia—Mesalazine—Crohn's disease	0.000944	0.00492	CcSEcCtD
Dabrafenib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000919	0.00479	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000913	0.00476	CcSEcCtD
Dabrafenib—RAF1—lymph node—Crohn's disease	0.000901	0.0256	CbGeAlD
Dabrafenib—Infestation—Mesalazine—Crohn's disease	0.0009	0.00469	CcSEcCtD
Dabrafenib—Infestation NOS—Mesalazine—Crohn's disease	0.0009	0.00469	CcSEcCtD
Dabrafenib—Haemoglobin—Azathioprine—Crohn's disease	0.000891	0.00464	CcSEcCtD
Dabrafenib—Haemorrhage—Azathioprine—Crohn's disease	0.000887	0.00462	CcSEcCtD
Dabrafenib—Renal failure—Mesalazine—Crohn's disease	0.000884	0.00461	CcSEcCtD
Dabrafenib—Stomatitis—Mesalazine—Crohn's disease	0.000877	0.00457	CcSEcCtD
Dabrafenib—Urinary tract infection—Mesalazine—Crohn's disease	0.000875	0.00456	CcSEcCtD
Dabrafenib—Haematuria—Mesalazine—Crohn's disease	0.000858	0.00447	CcSEcCtD
Dabrafenib—Epistaxis—Mesalazine—Crohn's disease	0.000849	0.00442	CcSEcCtD
Dabrafenib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000836	0.00435	CcSEcCtD
Dabrafenib—Haemoglobin—Mesalazine—Crohn's disease	0.000812	0.00423	CcSEcCtD
Dabrafenib—Haemorrhage—Mesalazine—Crohn's disease	0.000808	0.00421	CcSEcCtD
Dabrafenib—Immune system disorder—Azathioprine—Crohn's disease	0.000801	0.00417	CcSEcCtD
Dabrafenib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000799	0.00416	CcSEcCtD
Dabrafenib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000798	0.00416	CcSEcCtD
Dabrafenib—Oedema peripheral—Mesalazine—Crohn's disease	0.000796	0.00415	CcSEcCtD
Dabrafenib—Chills—Azathioprine—Crohn's disease	0.000796	0.00415	CcSEcCtD
Dabrafenib—Connective tissue disorder—Mesalazine—Crohn's disease	0.000794	0.00414	CcSEcCtD
Dabrafenib—Arrhythmia—Azathioprine—Crohn's disease	0.000792	0.00413	CcSEcCtD
Dabrafenib—Urethral disorder—Mesalazine—Crohn's disease	0.000792	0.00412	CcSEcCtD
Dabrafenib—Alopecia—Azathioprine—Crohn's disease	0.000784	0.00408	CcSEcCtD
Dabrafenib—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000779	0.00406	CcSEcCtD
Dabrafenib—Eye disorder—Mesalazine—Crohn's disease	0.000755	0.00393	CcSEcCtD
Dabrafenib—ABCG2—mammalian vulva—Crohn's disease	0.000744	0.0211	CbGeAlD
Dabrafenib—Angiopathy—Mesalazine—Crohn's disease	0.000733	0.00382	CcSEcCtD
Dabrafenib—Immune system disorder—Mesalazine—Crohn's disease	0.00073	0.0038	CcSEcCtD
Dabrafenib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000728	0.00379	CcSEcCtD
Dabrafenib—Chills—Mesalazine—Crohn's disease	0.000725	0.00378	CcSEcCtD
Dabrafenib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000723	0.00377	CcSEcCtD
Dabrafenib—Alopecia—Mesalazine—Crohn's disease	0.000714	0.00372	CcSEcCtD
Dabrafenib—Anaemia—Azathioprine—Crohn's disease	0.000713	0.00372	CcSEcCtD
Dabrafenib—Mental disorder—Mesalazine—Crohn's disease	0.000708	0.00369	CcSEcCtD
Dabrafenib—Erythema—Mesalazine—Crohn's disease	0.000703	0.00366	CcSEcCtD
Dabrafenib—Leukopenia—Azathioprine—Crohn's disease	0.000691	0.0036	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Prednisone—Crohn's disease	0.000681	0.00355	CcSEcCtD
Dabrafenib—Back pain—Mesalazine—Crohn's disease	0.00068	0.00354	CcSEcCtD
Dabrafenib—Muscle spasms—Mesalazine—Crohn's disease	0.000676	0.00352	CcSEcCtD
Dabrafenib—Vomiting—Mercaptopurine—Crohn's disease	0.000672	0.0035	CcSEcCtD
Dabrafenib—Rash—Mercaptopurine—Crohn's disease	0.000667	0.00347	CcSEcCtD
Dabrafenib—Dermatitis—Mercaptopurine—Crohn's disease	0.000666	0.00347	CcSEcCtD
Dabrafenib—Vision blurred—Mesalazine—Crohn's disease	0.000663	0.00345	CcSEcCtD
Dabrafenib—Myalgia—Azathioprine—Crohn's disease	0.000657	0.00342	CcSEcCtD
Dabrafenib—Arthralgia—Azathioprine—Crohn's disease	0.000657	0.00342	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000653	0.0034	CcSEcCtD
Dabrafenib—Anaemia—Mesalazine—Crohn's disease	0.00065	0.00339	CcSEcCtD
Dabrafenib—Leukopenia—Mesalazine—Crohn's disease	0.000629	0.00328	CcSEcCtD
Dabrafenib—Nausea—Mercaptopurine—Crohn's disease	0.000628	0.00327	CcSEcCtD
Dabrafenib—Infection—Azathioprine—Crohn's disease	0.000626	0.00326	CcSEcCtD
Dabrafenib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000617	0.00321	CcSEcCtD
Dabrafenib—Cough—Mesalazine—Crohn's disease	0.000614	0.0032	CcSEcCtD
Dabrafenib—Skin disorder—Azathioprine—Crohn's disease	0.000612	0.00319	CcSEcCtD
Dabrafenib—Hypertension—Mesalazine—Crohn's disease	0.000607	0.00316	CcSEcCtD
Dabrafenib—Myalgia—Mesalazine—Crohn's disease	0.000599	0.00312	CcSEcCtD
Dabrafenib—Arthralgia—Mesalazine—Crohn's disease	0.000599	0.00312	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000594	0.0031	CcSEcCtD
Dabrafenib—Hypotension—Azathioprine—Crohn's disease	0.000589	0.00307	CcSEcCtD
Dabrafenib—Dry mouth—Mesalazine—Crohn's disease	0.000585	0.00305	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000574	0.00299	CcSEcCtD
Dabrafenib—Oedema—Mesalazine—Crohn's disease	0.000574	0.00299	CcSEcCtD
Dabrafenib—Infection—Mesalazine—Crohn's disease	0.00057	0.00297	CcSEcCtD
Dabrafenib—Dry skin—Prednisone—Crohn's disease	0.000566	0.00295	CcSEcCtD
Dabrafenib—Nervous system disorder—Mesalazine—Crohn's disease	0.000563	0.00293	CcSEcCtD
Dabrafenib—Hypokalaemia—Prednisone—Crohn's disease	0.000562	0.00293	CcSEcCtD
Dabrafenib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000562	0.00293	CcSEcCtD
Dabrafenib—Skin disorder—Mesalazine—Crohn's disease	0.000557	0.0029	CcSEcCtD
Dabrafenib—Hyperhidrosis—Mesalazine—Crohn's disease	0.000555	0.00289	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000545	0.00284	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000544	0.00283	CcSEcCtD
Dabrafenib—Hypotension—Mesalazine—Crohn's disease	0.000536	0.00279	CcSEcCtD
Dabrafenib—Pancreatitis—Prednisone—Crohn's disease	0.000523	0.00273	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000523	0.00272	CcSEcCtD
Dabrafenib—Insomnia—Mesalazine—Crohn's disease	0.000519	0.0027	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000515	0.00268	CcSEcCtD
Dabrafenib—Neutropenia—Prednisone—Crohn's disease	0.000499	0.0026	CcSEcCtD
Dabrafenib—Decreased appetite—Mesalazine—Crohn's disease	0.000499	0.0026	CcSEcCtD
Dabrafenib—Abdominal pain—Azathioprine—Crohn's disease	0.000498	0.00259	CcSEcCtD
Dabrafenib—Body temperature increased—Azathioprine—Crohn's disease	0.000498	0.00259	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000495	0.00258	CcSEcCtD
Dabrafenib—Fatigue—Mesalazine—Crohn's disease	0.000495	0.00258	CcSEcCtD
Dabrafenib—Constipation—Mesalazine—Crohn's disease	0.000491	0.00256	CcSEcCtD
Dabrafenib—Hyperglycaemia—Prednisone—Crohn's disease	0.000482	0.00251	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000469	0.00244	CcSEcCtD
Dabrafenib—Hypersensitivity—Azathioprine—Crohn's disease	0.000464	0.00242	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—Crohn's disease	0.000454	0.0129	CbGeAlD
Dabrafenib—Abdominal pain—Mesalazine—Crohn's disease	0.000454	0.00236	CcSEcCtD
Dabrafenib—Body temperature increased—Mesalazine—Crohn's disease	0.000454	0.00236	CcSEcCtD
Dabrafenib—Diarrhoea—Azathioprine—Crohn's disease	0.000431	0.00225	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisone—Crohn's disease	0.00043	0.00224	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—Crohn's disease	0.000427	0.00223	CcSEcCtD
Dabrafenib—Hypersensitivity—Mesalazine—Crohn's disease	0.000423	0.0022	CcSEcCtD
Dabrafenib—ABCB1—epithelium—Crohn's disease	0.000423	0.012	CbGeAlD
Dabrafenib—Connective tissue disorder—Prednisone—Crohn's disease	0.00042	0.00219	CcSEcCtD
Dabrafenib—Dizziness—Azathioprine—Crohn's disease	0.000417	0.00217	CcSEcCtD
Dabrafenib—Asthenia—Mesalazine—Crohn's disease	0.000412	0.00214	CcSEcCtD
Dabrafenib—Pruritus—Mesalazine—Crohn's disease	0.000406	0.00212	CcSEcCtD
Dabrafenib—Vomiting—Azathioprine—Crohn's disease	0.000401	0.00209	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—Crohn's disease	0.000399	0.00208	CcSEcCtD
Dabrafenib—Rash—Azathioprine—Crohn's disease	0.000397	0.00207	CcSEcCtD
Dabrafenib—Dermatitis—Azathioprine—Crohn's disease	0.000397	0.00207	CcSEcCtD
Dabrafenib—Headache—Azathioprine—Crohn's disease	0.000395	0.00206	CcSEcCtD
Dabrafenib—Diarrhoea—Mesalazine—Crohn's disease	0.000393	0.00205	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—Crohn's disease	0.000388	0.00202	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—Crohn's disease	0.000386	0.00201	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—Crohn's disease	0.000382	0.00199	CcSEcCtD
Dabrafenib—Dizziness—Mesalazine—Crohn's disease	0.000379	0.00198	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—Crohn's disease	0.000378	0.00197	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—Crohn's disease	0.000374	0.00195	CcSEcCtD
Dabrafenib—Nausea—Azathioprine—Crohn's disease	0.000374	0.00195	CcSEcCtD
Dabrafenib—ABCG2—lymph node—Crohn's disease	0.000373	0.0106	CbGeAlD
Dabrafenib—Erythema—Prednisone—Crohn's disease	0.000372	0.00194	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—Crohn's disease	0.000372	0.00194	CcSEcCtD
Dabrafenib—ABCB1—mammalian vulva—Crohn's disease	0.000367	0.0104	CbGeAlD
Dabrafenib—Vomiting—Mesalazine—Crohn's disease	0.000365	0.0019	CcSEcCtD
Dabrafenib—Rash—Mesalazine—Crohn's disease	0.000362	0.00189	CcSEcCtD
Dabrafenib—Dermatitis—Mesalazine—Crohn's disease	0.000361	0.00188	CcSEcCtD
Dabrafenib—Headache—Mesalazine—Crohn's disease	0.000359	0.00187	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—Crohn's disease	0.000351	0.00183	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—Crohn's disease	0.000344	0.00179	CcSEcCtD
Dabrafenib—Nausea—Mesalazine—Crohn's disease	0.000341	0.00178	CcSEcCtD
Dabrafenib—ABCB1—lymphoid tissue—Crohn's disease	0.000326	0.00924	CbGeAlD
Dabrafenib—ABCB1—digestive system—Crohn's disease	0.000322	0.00913	CbGeAlD
Dabrafenib—Hypertension—Prednisone—Crohn's disease	0.000321	0.00167	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—Crohn's disease	0.000317	0.00165	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—Crohn's disease	0.000317	0.00165	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000315	0.00164	CcSEcCtD
Dabrafenib—Oedema—Prednisone—Crohn's disease	0.000304	0.00158	CcSEcCtD
Dabrafenib—Infection—Prednisone—Crohn's disease	0.000302	0.00157	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—Crohn's disease	0.000298	0.00155	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—Crohn's disease	0.000295	0.00154	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—Crohn's disease	0.000294	0.00153	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000277	0.00144	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—Crohn's disease	0.000275	0.00143	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—Crohn's disease	0.000264	0.00138	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—Crohn's disease	0.000262	0.00136	CcSEcCtD
Dabrafenib—Constipation—Prednisone—Crohn's disease	0.00026	0.00135	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—Crohn's disease	0.000248	0.00129	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—Crohn's disease	0.00024	0.00125	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—Crohn's disease	0.00024	0.00125	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—Crohn's disease	0.000224	0.00117	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—Crohn's disease	0.000218	0.00113	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—Crohn's disease	0.000215	0.00112	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—Crohn's disease	0.000208	0.00108	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—Crohn's disease	0.000201	0.00105	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—Crohn's disease	0.000193	0.00101	CcSEcCtD
Dabrafenib—Rash—Prednisone—Crohn's disease	0.000191	0.000997	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—Crohn's disease	0.000191	0.000996	CcSEcCtD
Dabrafenib—Headache—Prednisone—Crohn's disease	0.00019	0.000991	CcSEcCtD
Dabrafenib—ABCB1—lymph node—Crohn's disease	0.000184	0.00521	CbGeAlD
Dabrafenib—Nausea—Prednisone—Crohn's disease	0.00018	0.00094	CcSEcCtD
Dabrafenib—RAF1—Signaling by SCF-KIT—STAT3—Crohn's disease	9.15e-05	0.000451	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—TLR4—Crohn's disease	9.15e-05	0.000451	CbGpPWpGaD
Dabrafenib—RAF1—Disease—LTF—Crohn's disease	9.11e-05	0.000449	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—UBE2D1—Crohn's disease	9.07e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—STAT3—Crohn's disease	9e-05	0.000444	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—IL6—Crohn's disease	9e-05	0.000443	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IL6—Crohn's disease	9e-05	0.000443	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—IL6—Crohn's disease	9e-05	0.000443	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLA2G4F—Crohn's disease	8.95e-05	0.000441	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GPX4—Crohn's disease	8.92e-05	0.00044	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	8.9e-05	0.000439	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—RIPK2—Crohn's disease	8.8e-05	0.000434	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	8.79e-05	0.000433	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	8.79e-05	0.000433	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ICAM1—Crohn's disease	8.77e-05	0.000432	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GPR65—Crohn's disease	8.74e-05	0.000431	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—UBE2D1—Crohn's disease	8.71e-05	0.000429	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	8.7e-05	0.000429	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GCKR—Crohn's disease	8.62e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TAGAP—Crohn's disease	8.58e-05	0.000423	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	8.53e-05	0.00042	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—ALB—Crohn's disease	8.51e-05	0.00042	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—RIPK2—Crohn's disease	8.45e-05	0.000416	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ITGA4—Crohn's disease	8.45e-05	0.000416	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—Crohn's disease	8.4e-05	0.000414	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—RASGRP1—Crohn's disease	8.3e-05	0.000409	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—IL6—Crohn's disease	8.27e-05	0.000408	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	8.26e-05	0.000407	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—STAT3—Crohn's disease	8.23e-05	0.000406	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTMR3—Crohn's disease	8.22e-05	0.000405	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	8.19e-05	0.000404	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL1B—Crohn's disease	8.18e-05	0.000403	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TAB1—Crohn's disease	8.12e-05	0.0004	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—Crohn's disease	8.09e-05	0.000399	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HSPA1B—Crohn's disease	8.04e-05	0.000396	CbGpPWpGaD
Dabrafenib—BRAF—Disease—RBX1—Crohn's disease	8.04e-05	0.000396	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NOD2—Crohn's disease	7.98e-05	0.000393	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	7.97e-05	0.000393	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—RASGRP1—Crohn's disease	7.97e-05	0.000393	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD79A—Crohn's disease	7.94e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—Crohn's disease	7.91e-05	0.00039	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—ALB—Crohn's disease	7.74e-05	0.000382	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	7.74e-05	0.000381	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—Crohn's disease	7.7e-05	0.00038	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—STAT3—Crohn's disease	7.63e-05	0.000376	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTMR3—Crohn's disease	7.61e-05	0.000375	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—TYK2—Crohn's disease	7.55e-05	0.000372	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—Crohn's disease	7.53e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SOCS1—Crohn's disease	7.52e-05	0.00037	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—STAT3—Crohn's disease	7.51e-05	0.00037	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RSPO3—Crohn's disease	7.5e-05	0.00037	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—Crohn's disease	7.47e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—STAT3—Crohn's disease	7.46e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—TYK2—Crohn's disease	7.42e-05	0.000366	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SMAD3—Crohn's disease	7.35e-05	0.000362	CbGpPWpGaD
Dabrafenib—RAF1—Disease—GCKR—Crohn's disease	7.34e-05	0.000362	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NOD1—Crohn's disease	7.34e-05	0.000362	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR6—Crohn's disease	7.29e-05	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SOCS1—Crohn's disease	7.22e-05	0.000356	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—JAK2—Crohn's disease	7.2e-05	0.000355	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—TYK2—Crohn's disease	7.13e-05	0.000351	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SEL1L—Crohn's disease	7.11e-05	0.00035	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—JAK2—Crohn's disease	7.08e-05	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—Crohn's disease	7.07e-05	0.000348	CbGpPWpGaD
Dabrafenib—BRAF—Disease—UBE2D1—Crohn's disease	7.05e-05	0.000348	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—Crohn's disease	6.89e-05	0.000339	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	6.82e-05	0.000336	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—JAK2—Crohn's disease	6.8e-05	0.000335	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—Crohn's disease	6.78e-05	0.000334	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—Crohn's disease	6.76e-05	0.000333	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—TYK2—Crohn's disease	6.72e-05	0.000331	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—Crohn's disease	6.68e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2RA—Crohn's disease	6.67e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CCR6—Crohn's disease	6.66e-05	0.000328	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR9—Crohn's disease	6.5e-05	0.000321	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SLC11A1—Crohn's disease	6.49e-05	0.00032	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—Crohn's disease	6.45e-05	0.000318	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTGER4—Crohn's disease	6.42e-05	0.000316	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—JAK2—Crohn's disease	6.41e-05	0.000316	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—FADS1—Crohn's disease	6.4e-05	0.000316	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—Crohn's disease	6.39e-05	0.000315	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—Crohn's disease	6.31e-05	0.000311	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR6—Crohn's disease	6.23e-05	0.000307	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	6.21e-05	0.000306	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	6.19e-05	0.000305	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.16e-05	0.000304	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—Crohn's disease	6.12e-05	0.000301	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTPN2—Crohn's disease	6.09e-05	0.0003	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GPR65—Crohn's disease	6.05e-05	0.000298	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RBX1—Crohn's disease	6.03e-05	0.000297	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—Crohn's disease	6.02e-05	0.000297	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX4—Crohn's disease	6e-05	0.000296	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—Crohn's disease	5.99e-05	0.000295	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—Crohn's disease	5.95e-05	0.000293	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—Crohn's disease	5.94e-05	0.000293	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—FADS1—Crohn's disease	5.93e-05	0.000292	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—Crohn's disease	5.86e-05	0.000289	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GCKR—Crohn's disease	5.79e-05	0.000285	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—Crohn's disease	5.75e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—Crohn's disease	5.72e-05	0.000282	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—Crohn's disease	5.69e-05	0.000281	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CRP—Crohn's disease	5.67e-05	0.000279	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—Crohn's disease	5.66e-05	0.000279	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RBX1—Crohn's disease	5.63e-05	0.000278	CbGpPWpGaD
Dabrafenib—RAF1—Disease—RBX1—Crohn's disease	5.56e-05	0.000274	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HSPA1B—Crohn's disease	5.56e-05	0.000274	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLA2G4F—Crohn's disease	5.55e-05	0.000274	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX4—Crohn's disease	5.55e-05	0.000274	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTGER4—Crohn's disease	5.48e-05	0.00027	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	5.47e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL3—Crohn's disease	5.47e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR4—Crohn's disease	5.43e-05	0.000268	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.39e-05	0.000266	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GCKR—Crohn's disease	5.36e-05	0.000264	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—Crohn's disease	5.33e-05	0.000263	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—Crohn's disease	5.33e-05	0.000263	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	5.33e-05	0.000263	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RASGRP1—Crohn's disease	5.29e-05	0.000261	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—STAT3—Crohn's disease	5.29e-05	0.000261	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—UBE2D1—Crohn's disease	5.28e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—Crohn's disease	5.28e-05	0.00026	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—Crohn's disease	5.25e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—Crohn's disease	5.24e-05	0.000258	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—Crohn's disease	5.21e-05	0.000257	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—STAT3—Crohn's disease	5.2e-05	0.000256	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—Crohn's disease	5.18e-05	0.000255	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RIPK2—Crohn's disease	5.12e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ITGA4—Crohn's disease	5.12e-05	0.000253	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SMAD3—Crohn's disease	5.04e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ICAM1—Crohn's disease	5e-05	0.000247	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL3—Crohn's disease	5e-05	0.000246	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—STAT3—Crohn's disease	4.99e-05	0.000246	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—UBE2D1—Crohn's disease	4.94e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Disease—UBE2D1—Crohn's disease	4.88e-05	0.00024	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLA2G4F—Crohn's disease	4.84e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RASGRP1—Crohn's disease	4.83e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—Crohn's disease	4.83e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD79A—Crohn's disease	4.82e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TYK2—Crohn's disease	4.79e-05	0.000236	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RIPK2—Crohn's disease	4.79e-05	0.000236	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TAB1—Crohn's disease	4.73e-05	0.000233	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTMR3—Crohn's disease	4.72e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	4.72e-05	0.000233	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL3—Crohn's disease	4.67e-05	0.00023	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NOD2—Crohn's disease	4.65e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—JAK2—Crohn's disease	4.57e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	4.56e-05	0.000225	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RASGRP1—Crohn's disease	4.52e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—JAK2—Crohn's disease	4.49e-05	0.000221	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SOCS1—Crohn's disease	4.38e-05	0.000216	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	4.34e-05	0.000214	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—Crohn's disease	4.33e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR6—Crohn's disease	4.31e-05	0.000212	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TYK2—Crohn's disease	4.23e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—Crohn's disease	4.18e-05	0.000206	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.14e-05	0.000204	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTMR3—Crohn's disease	4.11e-05	0.000203	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SOCS1—Crohn's disease	4.09e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—JAK2—Crohn's disease	4.04e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL18—Crohn's disease	3.94e-05	0.000194	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—Crohn's disease	3.94e-05	0.000194	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RBX1—Crohn's disease	3.9e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2RA—Crohn's disease	3.83e-05	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—Crohn's disease	3.83e-05	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTGER4—Crohn's disease	3.79e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—Crohn's disease	3.69e-05	0.000182	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—FADS1—Crohn's disease	3.68e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—Crohn's disease	3.68e-05	0.000181	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—Crohn's disease	3.64e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—Crohn's disease	3.63e-05	0.000179	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.62e-05	0.000178	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMAD3—Crohn's disease	3.53e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2RA—Crohn's disease	3.5e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SMAD3—Crohn's disease	3.49e-05	0.000172	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—Crohn's disease	3.49e-05	0.000172	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX4—Crohn's disease	3.45e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—UBE2D1—Crohn's disease	3.42e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—STAT3—Crohn's disease	3.36e-05	0.000165	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GCKR—Crohn's disease	3.33e-05	0.000164	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RIPK2—Crohn's disease	3.31e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—Crohn's disease	3.3e-05	0.000163	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TYK2—Crohn's disease	3.29e-05	0.000162	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—Crohn's disease	3.29e-05	0.000162	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2RA—Crohn's disease	3.27e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL3—Crohn's disease	3.23e-05	0.000159	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FADS1—Crohn's disease	3.21e-05	0.000158	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—Crohn's disease	3.17e-05	0.000156	CbGpPWpGaD
Dabrafenib—BRAF—Disease—JAK2—Crohn's disease	3.14e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RASGRP1—Crohn's disease	3.12e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ICAM1—Crohn's disease	3.03e-05	0.00015	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX4—Crohn's disease	3e-05	0.000148	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.98e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—Crohn's disease	2.98e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—Crohn's disease	2.95e-05	0.000146	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.93e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—Crohn's disease	2.91e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCKR—Crohn's disease	2.9e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SOCS1—Crohn's disease	2.83e-05	0.00014	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—Crohn's disease	2.74e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TYK2—Crohn's disease	2.7e-05	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—JAK2—Crohn's disease	2.57e-05	0.000127	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.54e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TYK2—Crohn's disease	2.47e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMAD3—Crohn's disease	2.44e-05	0.00012	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—Crohn's disease	2.4e-05	0.000118	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	2.38e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JAK2—Crohn's disease	2.35e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—Crohn's disease	2.35e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—Crohn's disease	2.34e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—Crohn's disease	2.31e-05	0.000114	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TYK2—Crohn's disease	2.3e-05	0.000114	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—Crohn's disease	2.3e-05	0.000114	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TYK2—Crohn's disease	2.28e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2RA—Crohn's disease	2.26e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—Crohn's disease	2.23e-05	0.00011	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JAK2—Crohn's disease	2.2e-05	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Disease—JAK2—Crohn's disease	2.17e-05	0.000107	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.08e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—Crohn's disease	2.07e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—Crohn's disease	2.06e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—Crohn's disease	2.06e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—Crohn's disease	2.04e-05	0.000101	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—Crohn's disease	2.01e-05	9.89e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FADS1—Crohn's disease	1.98e-05	9.73e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.97e-05	9.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX4—Crohn's disease	1.85e-05	9.12e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—Crohn's disease	1.84e-05	9.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCKR—Crohn's disease	1.79e-05	8.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—Crohn's disease	1.73e-05	8.51e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—Crohn's disease	1.71e-05	8.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—Crohn's disease	1.61e-05	7.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—Crohn's disease	1.61e-05	7.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—Crohn's disease	1.61e-05	7.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TYK2—Crohn's disease	1.59e-05	7.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—Crohn's disease	1.59e-05	7.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JAK2—Crohn's disease	1.52e-05	7.5e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—Crohn's disease	1.49e-05	7.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—Crohn's disease	1.39e-05	6.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—Crohn's disease	1.32e-05	6.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—Crohn's disease	1.21e-05	5.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—Crohn's disease	1.13e-05	5.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—Crohn's disease	1.12e-05	5.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—Crohn's disease	1.11e-05	5.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—Crohn's disease	1.06e-05	5.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—Crohn's disease	9.27e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—Crohn's disease	9.23e-06	4.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—Crohn's disease	8.07e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—Crohn's disease	7.8e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—Crohn's disease	5.68e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—Crohn's disease	4.97e-06	2.45e-05	CbGpPWpGaD
